Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of [C14] CT1812 in 8 healthy male subjects~Subjects will be screened 28-days prior to dosing to determine eligibility.~Eligible subjects will be admitted to the clinical research unit (CRU) on Day -1. On Day 1, subjects will receive a single dose of CT1812 with a microtracer dose of [14C] CT1812. Whole blood, plasma, urine and fecal samples will be collection during the confinement period. Safety will be monitored throughout the study by repeated clinical and laboratory evaluations.~Subjects will be and discharged from the CRU following completion of procedures 168 hours post dose (Day 8)
Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of [C14] CT1812